OpenLegislation

Regulation 2 Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002

Original text. Later amendments are not shown.

The Misuse of Drugs Regulations (Northern Ireland) 2002f1 are amended as follows.

(1)

In regulation 2 (2) (interpretation), in the definition of “cannabis-based product for medicinal use in humans”f2, for “Schedule 4 applies” substitute—

  • “Schedule 4, or paragraph 10 of Schedule 5, applies”.

(2)

In paragraph 1(a) of Schedule 1 (controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27), for “Cannabinol derivatives not being dronabinol or its stereoisomers” substitute—

  • “Cannabinol derivatives not being—

    1. (i)

      dronabinol or its stereoisomers; or

    2. (ii)

      the substance specified in paragraph 10 of Schedule 5.”

(3)

In Schedule 5 (controlled drugs excepted from the prohibition on importation, exportation and possession and subject to the requirements of regulations 24 and 26), after paragraph 9 insert—

“10.

A liquid formulation—

(a)

containing cannabidiol obtained by extraction and purification from cannabis;

(b)

where the concentration of—

(i)

delta-9-tetrahydrocannabinol is not more than 0.1 milligram per millilitre; and

(ii)

cannabidiol is 95-105 milligrams per millilitre;

(c)

which is presented in a bottle, as an oral solution for oral administration; and

(d)

which was approved for marketing by the European Commission on 19th September 2019.”.

Annotations

Footnotes

f1

S.R. 2002 No. 1. Relevant amending Regulations are S.R. 2020 No. 73, S.R. 2019 Nos. 208 and 21, S.R. 2018 Nos. 173 and 4, S.R. 2016 No. 29, S.R. 2015 No. 227, S.R. 2015 No. 53, S.R. 2014 Nos. 261, 158 and 21, S.R. 2013 No. 78, S.R. 2012 No. 213, S.R. 2011 No. 153, S.R. 2010 Nos. 247 and 148, S.R. 2009 No. 390, S.R. 2007 No. 348 and S.R. 2005 No. 360

f2

This definition was inserted by S.R. 2018 No. 173